GovChime
Notice ID: 35079a226fb848018218d646d505596fSolicitation

TRICARE Pharmacy Services, 5th Generation (TPharm5)

Archived on September 5, 2021. Original response deadline: . Full description on SAM.gov.

Overview

Response deadline
4:00 PM UTC−06:00
Posted
August 20, 2021
Notice type
Solicitation
NAICS
524114: Direct Health and Medical Insurance Carriers
Agency
Department of WarDEFENSE HEALTH AGENCY (DHA)

Notice details

Office
DEFENSE HEALTH AGENCY
Last updated
Sep 25, 2026

Identifiers

Solicitation number
HT940220R0002
Notice ID
35079a226fb848018218d646d505596f

Description

20201002 Amendment 00005 This amendment makes changes to the RFP document as well as attachments as listed in the amendment. Amendment 5 to HT940220R0002 includes revisions made to Section B - SUPPLIES OR SERVICES AND PRICES/COSTS, Section C - STATEMENT OF WORK, Section G - CONTRACT ADMINISTRATION, Section H - SPECIAL CONTRACT REQUIREMENTS, Section L - INSTRUCTIONS, CONDITIONS & NOTICES TO OFFERORS and Section M - EVALUATION FACTORS FOR AWARD. Attachment L-25 is amended. Amendment 5 also extends the proposal due date to 1200 Hrs Mountain Time on 10/23/2020. ************************************************************************** 20200929 Amendment 00004 This amendment makes changes to the RFP document as well as attachments as listed in the amendment. Amendment 4 to HT940220R0002 includes revisions made to Section G - CONTRACT ADMINISTRATION, and to Section L - INSTRUCTIONS, CONDITIONS & NOTICES TO OFFERORS. Amendment 4 also includes Government responses to additional questions about the solicitation which have been submitted by interested parties. ************************************************************************** 20200914 Amendment 00003 This amendment makes changes to the RFP document as well as attachments as listed in the amendment. Amendment 3 to HT940220R0002 includes revisions made to Section L - INSTRUCTIONS, CONDITIONS & NOTICES TO OFFERORS. Amendment 3 also includes Government responses to questions about the solicitation which have been submitted by interested parties (Attachment L-30). ************************************************************************** 20200901 Amendment 00002 This amendment makes changes to the RFP document as well as attachments as listed in the amendment. It also provides details for the Pre-Proposal Conference scheduled for 9/2/2020 at 11:00am MDT (See Attachment L-31) Amendment 2 to HT940220R0002 includes revisions made to Section B - SUPPLIES OR SERVICES AND PRICES/COSTS, Section C - STATEMENT OF WORK, Section G - CONTRACT ADMINISTRATION, Section H - SPECIAL CONTRACT REQUIREMENTS, Section I - CONTRACT CLAUSES, and Section L - INSTRUCTIONS, CONDITIONS & NOTICES TO OFFERORS. Also included in Amendment 2 are Government responses to questions about the solicitation submitted by interested parties, and a notice announcing the TPharm5 Pre-Proposal Conference. ************************************************************************** 20200810 Amendment 00001 This amendment makes changes to the RFP document as well as attachments as listed in the amendment. Amendment 00001 to HT940220R0002 includes revisions made to Section C - STATEMENT OF WORK, Section F - DELIVERIES OR PERFORMANCE, Section G - CONTRACT ADMINISTRATION, Section H - SPECIAL CONTRACT REQUIREMENTS, Section I - CONTRACT CLAUSES, Section J - LIST OF ATTACHMENTS, Section K - REPRESENTATIONS & CERTIFICATIONS, Section L - INSTRUCTIONS, CONDITIONS & NOTICES TO OFFERORS, and Section M - EVALUATION FACTORS FOR AWARD. ************************************************************************** This is the official release of the Request for Proposal (RFP) for the TRICARE Pharmacy, 5th Generation (TPharm5) requirement. TPharm5 is the continuing requirement to provide pharmacy benefits for the Military Health System (MHS) by providing access to prescription medications through a retail pharmacy network, dispensing prescriptions through a mail order pharmacy (MOP), and adjudicating Military Treatment Facility (MTF) prescriptions with all other prescriptions using a central patient profile reflecting transactions at all points of service using full and open competition. Potential offerors may submit questions by email to dha.buckley.acquis-procure.mbx.tpharm5@mail.mil Questions must be submitted no later than 1600 MDT on August 12, 2020. Questions and answers will be posted publically on the same RFP posting, if applicable. A virtual pre-proposal conference will be hosted on September 2, 2020. More details to follow. Potential offerors may request confidential and protected information at this time. The ordering instructions for confidential and protected information are located in Attachment L-1. Potential offers may submit these requests by email to dha.buckley.acquis-procure.mbx.tpharm5@mail.mil All responsible sources may submit a proposal. Proposals are due 1600 MDT, October 16, 2020. To receive emails concerning the status of this solicitation, interested parties are strongly encouraged to register as vendors on www.beta.SAM.gov and then sign up as interested vendors for solicitation HT940220R0002. It is the responsibility of the prospective offeror to review this site regularly for updates.

Full description on SAM.gov

Award Overview

No prior contract identified

No prior award matched this notice's agency, NAICS, place of performance and PSC within 18 months. It may be a new requirement.

Contacts

Contracting Officer

Secondary Contact

Documents

No documents available.

Lifecycle

Solicitation:HT940220R0002
  1. Pre-Solicitation
  2. Solicitation

Award typically follows within 30–90 days after the response deadline. (estimate)

  1. 10×
    Special NoticeDec 2, 2019

    DRAFT RFP TRICARE Pharmacy Services, 5th Generation (TPharm5)

    Notice 6275135525244143a5ac8292acf9b36f on SAM.gov

  2. Pre-SolicitationJun 15, 2020

    TRICARE Pharmacy Services, 5th Generation (TPharm5)

    Notice dd48214d5afe456e9d2ee928dc13355b on SAM.gov

  3. 7×
    SolicitationCurrentJul 13, 2020

    TRICARE Pharmacy Services, 5th Generation (TPharm5)

    Notice 35079a226fb848018218d646d505596f on SAM.gov

Similar Opportunities

Title
Match
Phase
Deadline
UPDATE: 11/06/2026 The Government received noteworthy interest in one-on-one meetings. The attachment labeled “Supplemental Cancer Insurance Pilot_Industry Event” contains crucial information for Vendor presentations. The Defense Health Agency continues market research with the following primary objectives: Investigate feasibility of no-cost, fixed indemnity supplemental cancer insurance for pilot eligible TRICARE beneficiaries based on industry interest and capability to meet requirements. Reduce financial burden and support beneficiary wellness, family resilience, and force readiness in the event of cancer diagnosis. Appraise potential value added to beneficiaries to inform pilot implementation and future policy regarding supplemental benefits. Virtual meetings will last approximately 1hr and are available on the following dates/times: 17NOV2026 @1000 EST 17NOV2026@ 1300 EST 17NOV2026@ 1500 EST 19NOV2026@ 1400 EST [alternate] Presentation materials will be due one business day before the event (16NOV). Please email Mr. James Goddard to reserve a one-on-one meeting. --------------------------------------------------------------------------------------------------------------------------------------------------------------------- UPDATE: 10/21/2026 The Government received several questions in the RFI submissions. The attachment labeled “RFI QA Responses HT940226RFI0255 Supplemental Pilot" is intended to address these questions. The DHA plans to continue gathering market intelligence by meeting with interested vendors. Vendor’s will be expected to address questions regarding their RFI submissions as well as general market intelligence needed by the Government and will be given the opportunity to ask the Government questions. Virtual meetings are anticipated to be held on 19 November 2026. Please email Mr. James Goddard to request a one-on-one meeting. ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- The Defense Health Agency (DHA) is currently in the planning phase for partnering with carriers of supplemental insurance focused on cancer coverage. This Request for Information (RFI) is intended to initiate market research efforts as the Government considers structuring processes to meet Congress’ intent. Section 734 of the National Defense Authorization Act (NDAA) for Fiscal Year (FY) 2026 (Enclosure 1) requires DHA to establish a pilot program not later than September 30, 2027, under which members of the regular component of the Army, Navy, Marine Corps, Air Force, or Space Force and their dependents enrolled in TRICARE may obtain supplemental cancer insurance for noncovered expenses under a fixed indemnity supplemental benefit. The supplemental coverage is intended to provide financial assistance for noncovered expenses related to cancer screening, diagnosis and treatment that are not otherwise covered by the health care benefits the individuals receive under chapter 55 of title 10, United States Code, or any other benefit provided by the Secretary of Defense. https://www.congress.gov/119/plaws/publ60/PLAW-119publ60.pdf RFI Instructions: Prepare and submit a written response addressing each of the questions below. This response shall not exceed 20 pages in length and should not be solely your company’s general capability statement but instead specifically address the Government’s topics listed in this RFI. Please send your responses to the Defense Health Agency, Managed Care Contracting Division james.goddard22.ctr@health.mil by Close of Business 18 September 2026. RFI Questions: Plan Types and Coverage Scope Describe how a TRICARE specific plan would differ from current commercially available plans. What non-covered services under TRICARE would be covered? Would there be portability options if a beneficiary is no longer eligible for TRICARE? How could your company intend to add value to TRICARE beneficiaries? Describe an applicable case scenario. Coverage Details and Exclusions Detail general coverages provided in similar plans. Would there be any key coverage exclusions and limitations, including but not limited to: Acts of War, specific cancer types, pregnancy, and state-based restrictions? What annual or lifetime maximums on benefits would apply, and what conditions or treatments would be subject to caps or exceptions? What coverage would be provided for non-FDA approved drugs, participation in clinical trials, or other emerging and unproven treatments? Would pre-existing conditions be covered? If yes, what conditions would be included? Would there be any coverage limitations for a recurring diagnosis (remission or new)? In which states does your company offer coverage, and are there any state specific exceptions or restrictions that would apply to a TRICARE specific plan? How would this impact our mobile beneficiary population? Do your company’s plans provide coverage for beneficiaries residing or receiving care overseas? Eligibility and Enrollment Per the NDAA, the Government will not be subsidizing this pilot. To be financially viable, is there a minimum required enrollment threshold for such an unsubsidized, “no cost,” 100% beneficiary paid, group plan to be offered by your company? Is there a preferred eligibility verification process? What would prevent a member from being eligible? Describe the enrollment process and the expected burden on the beneficiary. When would coverage be effective? Any limitations? How would beneficiaries make premium payments? How are premiums structured today (in similar policies)? How would your company structure TRICARE premiums based on pilot requirements? Would premium rates be locked in for the duration of the pilot? Describe the termination of coverage process and the expected burden on the beneficiary. Claims and Payments How are claim payments determined and processed, including if lump sum payments are one-time or recurring, and any applicable limitations? Would payments be taxable as income? How would beneficiaries submit claims/receive payments, and what is the expected burden on the beneficiary? Would there be any third-party liability? If so, please explain. Describe the claims submissions and processing experience, including the average processing time and the availability of digital tools (such as online portals or mobile apps) for beneficiaries to submit and track claims. Reporting and Oversight What beneficiary data would your company provide to the Government/employer (e.g. cost, number of enrollees, denials, customer satisfaction, use case data)? Are there any limitations to data your company would be willing to share? Does your company recommend any specific data metrics DHA should track to accurately report the program’s success, beneficiary satisfaction, and programmatic feasibility to Congress? What board or organization oversees the supplemental insurance industry? Give some examples of standards, grievances, or reporting at a state or federal level. Qualifications How many years of experience does your company have providing supplemental insurance plans? What is your company’s claims acceptance/denial rate? What are the top 10 reasons for denials? How will your company protect beneficiaries’ personally identifiable information? Acquisition Strategy What are ways to participate via “no-cost” or similar means? Does your company anticipate any barriers to participating in the pilot based on “no-cost” contract terms? The Government may publish future RFIs or hold an industry day. Communication for both will be made under the same announcement as the RFI. The Government appreciates the time and expense related to this posting. Disclaimer: This announcement does not constitute a commitment, implied or otherwise, to ensure that a solicitation or contract will be issued. Issuance of the RFI is for planning purposes only and does not commit the Government to any contractual agreements or arrangements. The Government is not soliciting proposals with this request. Responses to this announcement will not be returned. The Government is not liable to pay any costs associated with companies responding to this announcement. Issuance of the RFI is intended to provide interested parties with information and provide an opportunity for industry feedback into the preliminary programmatic design. All information received resulting from this RFI will be used by the DHA for market research purposes and programmatic design. However, responses may be releasable to the public under the Freedom of Information Act (FOIA) unless appropriately marked. The DHA, at its discretion, may request respondents to elaborate on information in their written response in writing or through other means. Respondents will not be notified of any results derived from a review of the information provided. Any responses from the Government are subject to change, interested parties will have opportunity to seek clarification from the Government for any remaining questions. CONFIDENTIALITY: No proprietary, classified, confidential, or sensitive information should be included in your response. Industry responses will be shared with DHA staff for the purpose of market research. The Government reserves the right to use any non-proprietary technical information in any resultant solicitation(s). Potential offerors are instructed to use the question matrix provided in the attachments section for any additional comments or questions for the Government. Responses will be provided at a later date. PRIMARY DHA POINT OF CONTACT: email: marcus.r.webb.civ@health.mil
73%
Special Notice11/30/2026
28 Oct 2026: The TRICARE Medicare Eligible Program Second Generation SAM.gov posting is being updated to reflect a change in proposal due date. The new due date for TMEP2 RFP Proposals is December 03, 2026, at 5.p.m. MST.The DHA anticipates to have responses to questions before receipt of proposals out within the next few weeks. An RFP amendment will follow the Q&A posting to SAM.gov to address questions raised on the Q&A. 25 Sep 2026: Uploaded signed version of the basic RFP and Amendment 0001 that updates the sensitivity labels of Section J, Attachment J-5b and Exhibits L-7, L-8, L-9. This acquisition is for the continuing requirement for health care claims processing, customer support and other associated administrative services (e.g. submission of TRICARE encounter data and provider certification) of dual-eligible Medicare and TRICARE beneficiaries who receive medical services within the United States, Puerto Rico, Guam, US Virgin Islands, American Samoa, and Northern Mariana Islands. USC Title 10, Chapter 55, and USC Title 32, National Defense, Code of Federal Regulations (CFR) Part 199, outline the benefit structure, administrative functions and the various health care programs, including TMEP2. This is a full and open competitive source selection, using best value trade-off procedures in accordance with RFO Federal Acquisition Regulation (RFO FAR) 15.2, Evaluation and Award, as supplemented with Defense FAR Supplement and the DoD Source Selection Procedures (August 2022). The contract awarded will be a Firm Fixed-Price contract. The contract will have a one 12-month base period of transiotion-in activiteis, seven 1-year periods for healthcare delivery, a one 12-month contract period for transition-out activities, and a potential 6-month extension of services permitted per RFO FAR Clause 52.217-8, Option to Extend Services, for a potential total period of performance of 8.5 years.
70%
Combined Synopsis12/03/2026
59%
Sole Source / J&AOpen
See attached document: Attachment 1 - Justification Approval Redacted R2.
59%
Sole Source / J&AOpen
See attached document: Attachment 1 - Justification Approval Redacted R2.
59%
Sole Source / J&AOpen

Additional Details

Solicitation Number

HT940220R0002

Archive Date

Sep 5, 2021

Office Address

AURORA, CO, 80011